Sinopia Biosciences Publishes Preclinical Data in Science Translational Medicine Supporting SB-0110, a Novel PKA-II Modulator, for Parkinson's Disease
· sinopia biosciences, inc.
Source Summary
Study in highly translatable non-human primate models demonstrate how selective PKA-II modulation in combination with levodopa improved motor benefit while reducing dyskinesia
Advertisement